JNJ Stock Tumbles Amid Clinical Trial Setback

Johnson & Johnson (JNJ) has announced that its experimental treatment JNJ-5120/PIPE-307 failed to meet the primary endpoint in the MOONLIGHT-1 phase 2 trial for major depressive disorder.

This setback adds to previous challenges with the same compound in multiple sclerosis, raising questions about its future. Despite this, JNJ's dividend profile and financial metrics continue to draw investor attention.

The company offers a dividend yield of 1.95%, supported by a moderate payout ratio of 50% and a steady 3-year dividend growth rate of 4.9%. However, the stock is currently trading 37.8% above its intrinsic GF Value of $193.33.